07th week of 2009 patent applcation highlights part 48 |
Patent application number | Title | Published |
20090042753 | Method for enhancing the oxidation and nitration resistance of natural gas engine oil compositions and such compositions - The resistance to oxidation and nitration of a gas engine oil is improved by the use of a combination of a hindered phenolic antioxidant and an (alkylated) phenyl-α-naphthylamine antioxidant. The additional use of an organo molybdenum compound further enhances the resistance to oxidation and nitration. | 2009-02-12 |
20090042754 | METHOD OF IMPROVING RUST INHIBITION OF A LUBRICATING OIL - A method of improving the rust inhibition of a lubricating oil by incorporating a solubility improver having an aniline point less than 10° C. A method of improving the rust inhibition of a lubricating oil by incorporating a solubility improver to enable the lubricating oil to meet the requirements of the MIL-PRF-17331J specification. A method of improving the rust inhibition of a lubricating oil by incorporating a solubility improver, a mixture of mono and diacid amine phosphate salts, and a alkenyl succinic compound into the lubricating oil. | 2009-02-12 |
20090042755 | FINISHED LUBRICANT WITH IMPROVED RUST INHIBITION - A finished lubricant having a kinematic viscosity at 40° C. between about 90 and 1700 cSt that passes the TORT B rust test, comprising a highly paraffinic base oil and a solubility improver having an aniline point less than 50° C. A finished lubricant that passes the TORT B rust test, comprising a Fischer-Tropsch wax, oligomerized olefins, or mixture thereof; and a solubility improver. A process for making a lubricant, comprising blending together: a) a mixture of amine phosphates, b) an alkenyl succinic compound, and c) a highly paraffinic lubricating base oil. | 2009-02-12 |
20090042756 | Dental Appliance Cleansing Composition - A novel and safe composition has been discovered that is effective for cleaning dental appliances (e.g. removable braces, retainers, dentures, etc.). This composition bleaches, disinfects, and deodorizes the appliance, while removing plaque that has accumulated on the appliance during wear. The composition comprises a chloramine bleaching agent that liberates hypochlorous acid upon contact with water, a surfactant, a water-soluble carboxylic acid and an alkaline base to produce effervescence and regulate pH, a sequestering agent for alkaline earth metal ions, a drying agent, and an indicator dye that signifies the end of the cleansing process. In a preferred method of using this invention, the premixed components are added to water, and the dental appliance is submerged in the resulting effervescent solution until a color change indicates that cleaning is complete. This invention provides a safe, effective, and convenient method for cleansing and disinfecting dental appliances. | 2009-02-12 |
20090042757 | Monitoring Cleaning of Surfaces - A method for monitoring cleaning of a surface includes applying an amount of transparent indicator material to an area of a surface and measuring the amount of transparent indicator material remaining on the surface. The transparent indicator material may be fixed on the surface by drying and, when a fluorescent material, may be measured through exposure to ultraviolet radiation. | 2009-02-12 |
20090042758 | CLEANSING COMPOSITION - The present invention is related to an aqueous cleansing composition especially for keratin fibres such as human hair with shine enhancing effect. Accordingly the subject of the present invention is an aqueous cleansing composition especially for keratin fibres such as human hair comprising at least one anionic surfactant, at least one non-ionic surfactant and at least one amphoteric surfactant at a total concentration of 5 to 50% by weight calculated to total composition, and at least one arylated silicone at a concentration of 0.001 to 2.5% by weight, calculated to total composition. | 2009-02-12 |
20090042759 | ENCAPSULATED FRAGRANCE CHEMICALS - A polymeric encapsulated fragrance is disclosed which is suitable for use in personal care and cleaning products. In a preferred embodiment of the invention, the fragrance is encapsulated by a first polymer material to form a fragrance encapsulated polymer, the polymer encapsulated shell is then coated with a mixture of cationic polymers, in a preferred embodiment the coating polymers are a reaction product of polyamines (including 1H-imidazole) and (chloromethyl) oxirane or (bromomethyl) oxirane. | 2009-02-12 |
20090042760 | PRE-SOAPED, DISPOSABLE LUFFAH - Described is a pre-soaped, disposable luffah. The luffah of the type having a series of ruffles, is impregnated or coated with a cleansing and/or moisturizing agent such that a separate cleansing and/or moisturizing agent does not need to be applied to the luffah. The luffah may be impregnated or coated with the cleansing and/or moisturizing agent in any number of ways including submerging luffahs in a substantially wet, cleansing and/or moisturizing agent or spraying the substantially wet, cleansing and/or moisturizing agent on the luffahs. Once the substantially wet, cleansing and/or moisturizing agent is applied, the luffahs are dried until the substantially wet, cleansing and/or moisturizing agent forms into a substantially dry, cleansing and/or moisturizing agent on the luffah ruffles. | 2009-02-12 |
20090042761 | SOLUTION AND METHOD FOR CLEANING AND RESTORATION OF HEADLIGHT LENSES - A solution for cleaning plastic headlight covers that includes an oily acid, a surfactant, a citrus turpene and hard nanoparticles of sapphire and diamond. Principal ingredients are carried by commercial windshield cleaning solution or in water. | 2009-02-12 |
20090042762 | CLEANER COMPOSITION FOR REMOVAL OF LEAD-FREE SOLDERING FLUX, RINSING AGENT FOR REMOVAL OF LEAD-FREE SOLDERING FLUX, AND METHOD FOR REMOVAL OF LEAD-FREE SOLDERING FLUX - The present invention provides a cleaner composition that can satisfactorily remove lead-free soldering flux adhered to the object to be cleaned, has little impact on the environment, and has odor, inflammability, etc., which are of an acceptable level for practical use; a rinsing agent for rinsing the cleaned object after cleaning with the cleaner composition to remove lead-free soldering flux more effectively; and a removal method using the composition (and the rinsing agent). The cleaner composition for the removal of lead-free soldering flux contains:
| 2009-02-12 |
20090042763 | Aqueous cleaning composition - An aqueous acidic cleaning composition suitable for the cleaning of metal parts is constituted by urea phosphate, a surfactant, a corrosion inhibitor, and water. The corrosion inhibitor can be a phosphatizing compound such as iron phosphate, zinc phosphate, manganese phosphate, and the like. | 2009-02-12 |
20090042764 | Cleaning Agent Comprising Complexes with Bleach Catalytic Activity - Hard surface cleaning agents comprising a macrocyclic compound of the general formula L: | 2009-02-12 |
20090042765 | Fabric enhancers comprising nano-sized lamellar vesicle - A fabric enhancer comprising: at least one cationic softening compound, wherein said cationic softening compound comprises a plurality of lamellar vesicles, said lamellar vesicles having an average diameter from about 10 nm to about 170 nm, wherein said fabric enhancer is capable of forming phase stable mixtures with enhanced stability in the presence of at least one cationic polymer and processes for making the same. | 2009-02-12 |
20090042766 | Solid Textile Care Composition Comprising A Water-Soluble Polymer - A solid textile care composition having a water-soluble carrier, a water-soluble polymer, a textile care compound and a perfume. A solid textile care composition in which the water-soluble carrier is present in particulate form and has an envelope composed of the water-soluble polymer, the textile care compound and the perfume. Also textile care washing or cleaning compositions comprising the textile care composition. | 2009-02-12 |
20090042767 | Clear and/or translucent fabric enhancers comprising nano-sized particles - A fabric enhancer comprising: at least one fabric softening active, wherein said at least one fabric softening active comprises a plurality of particles comprising an intensity weighted particle size distribution wherein greater than about 95% of said plurality of particles have a size below about 170 nm. | 2009-02-12 |
20090042768 | Purine derivatives and their use for treatment of autoimmune diseases - Compounds useful in the treatment of autoimmune disease are described by the following general formula: | 2009-02-12 |
20090042769 | MODIFICATIONS OF PEPTIDE COMPOSITIONS TO INCREASE STABILITY AND DELIVERY EFFICIENCY - The disclosed invention relates to methods of modifying peptide compositions to increase stability and delivery efficiency. Specifically, the disclosed invention relates to methods to increase the stability and delivery efficiency of protein kinase C (PKC) modulatory peptide compositions. A “therapeutic peptide composition” comprises a “carrier peptide” and a “cargo peptide.” A “carrier peptide” is a peptide or amino acid sequence within a peptide that facilitates the cellular uptake of the therapeutic peptide composition. The “cargo peptide” is a PKC modulatory peptide. Peptide modifications to either the carrier peptide, the cargo peptide, or both, which are described herein increase the stability and delivery efficiency of therapeutic peptide compositions by reducing disulfide bond exchange, physical stability, reducing proteolytic degradation, and increasing efficiency of cellular uptake. | 2009-02-12 |
20090042770 | Branched Chain Amino Acid Chelate - Compositions are disclosed comprising mineral/branched-chain amino acid chelates such as, for example, calcium leucinate, for increasing absorption of the branched-amino acid in a human or animal subject. Methods are also provided for using the compositions to increase branched-chain amino acid absorption to increase or maintain muscle mass in athletes or in individuals having diseases such as ALS, muscular dystrophy, sarcopenia associated with aging, or muscle atrophy associated with spinal cord injury, as well as to decrease mental fatigue. | 2009-02-12 |
20090042771 | DIETARY LIPIDS FOR IMPROVING SKIN AND COAT OF PETS - A source of dietary lipids containing anti-microbial fatty acids is added to a food composition intended for improving or maintaining the skin health and/or coat quality in a pet by preventing or regulating the growth of skin pathogens and of microflora responsible for the generation of body surface and coat odors. | 2009-02-12 |
20090042772 | COMPOUNDS AND METHODS OF TREATING INSULIN RESISTANCE AND CARDIOMYOPATHY - Novel compounds, compositions comprising compounds, and methods for methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular system, atherosclerosis, sepsis, type 1 diabetes, liver damage, and cachexia, by administering compounds described herein. Compounds presented herein may be used to modulate serine palmitoyl transferase activity. | 2009-02-12 |
20090042773 | P13 kinase gamma inhibitors for the treatment of anaemia - This present invention is related to the use of selective PD Kinase gamma inhibitors for the manufacture of a medicament for the treatment of disorders related to erythrocyte deficiency. Specifically, the present invention is related to the use of selective PI3 Kinase gamma inhibitors, e.g. substituted azolidinone-vinyl fused-benzene derivatives for the treatment of an anaemia, including haemolytic anaemia, aplastic anaemia and pure red cell anaemia. (I) wherein A, X, Y | 2009-02-12 |
20090042774 | Parathyroid hormone analogues and methods of use - The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects. | 2009-02-12 |
20090042775 | Defensin Proteins - This invention relates to novel proteins, termed INSP 108 and INSP 109, herein identified as members of the defensin family of proteins and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease. | 2009-02-12 |
20090042776 | Fungal immunomodulatory protein (fip) prepared by microorganisms and uses thereof - The invention relates to an improved nucleic acid molecule encoding fungal immunomodulatory protein (FIP) that is better expressed in fungi, to vectors comprising the nucleic acid molecule, to hosts transformed with said vectors, to processes of expressing the protein of the invention in said transformed hosts, to the protein of the invention produced by said processes, to uses of said hosts comprising the protein of the invention and to a process of purifying FIP. The protein of the invention has wide immunomodulatory activity. Thus, the present invention further relates to uses of the protein of the invention in cosmetic or pharmaceutical compositions and to food or feed additives comprising the protein of the invention. Finally, the invention relates to the method of modulating immunological activities by orally administering FIP or proteins fused with FIP to a subject. | 2009-02-12 |
20090042777 | G-CSF Transferrin Fusion Proteins - A polypeptide comprising a G-CSF domain operably linked to a Tf domain, wherein the ability of the polypeptide to be transported into a cell expressing a TfR gene or the ability of the polypeptide to be transported across a cell expressing a TfR gene via transcytosis is higher than that of the G-CSF domain alone. | 2009-02-12 |
20090042778 | Methods for Suppressing Neovascularization Using Ephrinb2 - Methods for inhibiting DNA synthesis, MAP kinase activation, and tube formation of endothelial cells are provided. Also provided are methods for inhibiting angiogenesis and neovascularization, as well as compositions useful for the methods described herein. | 2009-02-12 |
20090042779 | Purified Extract of an Alpha-Amylase Inhibitor From Phytoemagglutinin-Essentially Free Beans, Process for Its Extraction and Compositions Containing It - The invention relates to the use of beans essentially free from phytohemagglutinin for extracting the alpha-amylase inhibitor (hereinafter also “phaseolamin”), the extract enriched in phaseolamin, the highly purified extract, and also the dietetic and pharmaceutical compositions that contain it; the invention also relates to a process for preparing the above extract and for the immobilisation of phaseolamin on an inert solid support. | 2009-02-12 |
20090042780 | Modified TGF-Beta Superfamily Polypeptides and Related Methods - The disclosure relates to modified TGF-beta polypeptides. Certain modified polypeptides disclosed herein are chimeric, containing a conserved framework portion from one protein of this family (e.g., Nodal) and variable loops that mediate receptor interaction derived from a second protein of this family (e.g., BMP-2). The chimeras will generally be designed so as to mimic a biological effect of the family member from which the variable loops are derived. Other modified TGF-polypeptides disclosed herein have one or more post-translational modifications that may be situated in one or more core domains. | 2009-02-12 |
20090042781 | Methods for Treating Diabetes - Methods for treating diabetes by increasing the insulin secretion by administration of a GLP-1 receptor agonist and/or a DPP-IV inhibitor in combination with a proton pump inhibitor and optionally a PPAR agonist are provided. | 2009-02-12 |
20090042782 | Diagnostic and therapeutic strategies for conditions associated with the FLJ13639 gene - Provided are methods for determining a prognosis for an individual suspected of having or diagnosed with cancer, where a high CD24/low FLJ13639 ratio indicates an unfavorable prognosis. Also provided are methods for enhancing the activity of chemotherapeutic agents, and isolated, purified FLJ13639 proteins for use in improving the prognosis of an individual and for enhancing the activity of chemotherapeutic agents. | 2009-02-12 |
20090042783 | APO E ANALOGS AND METHODS FOR THEIR USE - Novel ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including CNS inflammation, traumatic brain injury, cerebral ischema, Alzheimer's Disease and other brain disorders. | 2009-02-12 |
20090042784 | Purification of a Drug Substance of a Factor VII Polypeptide by Removal of DesGla-Factor VII Polypeptide Structures - The present invention relates to a purification process for drug substances of a Factor VII polypeptide having an impurity in the form of desGla-Factor VII polypeptide structures. The process utilizes an anion-exchange material and includes washing and/or elution with a buffer of a predetermined pH. | 2009-02-12 |
20090042785 | Compound with Affinity for the Cytotoxic T Lymphocyte-Associated Antigen (Ctla-4) - The present invention relates to a compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein the compound exhibits a synergistic mode of action in that the compound: (a) increases T cell priming or T cell expansion or the generation of memory T cells by blocking of CTLA-4, and (b) enhances effector T cell activity in tumor tissue or lymphoid tissue by blocking of CTLA-4. The compound of the invention can be a protein, a small organic molecule, a peptide, or a nucleic acid. The invention also relates to a mutein derived from a protein selected from the group consisting of human neutrophil gelatinase-associated lipocalin (hNGAL), rat α2-microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3), said mutein having binding specificity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein said mutein: (a) comprises amino acid replacements at least one of the sequence position corresponding to sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, and (b) binds human CTLA-4 with a K | 2009-02-12 |
20090042786 | Kunitz-type recombinant inhibitor - The present invention presents a Kunitz-type recombinant inhibitor obtained from a gene cloned from a cDNA library of salivary glands of the | 2009-02-12 |
20090042787 | Proteolytically cleavable fusion proteins with high molar specific activity - The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV (SEQ ID NO: 94). | 2009-02-12 |
20090042788 | Peptides and chemical compound for inhibition of SHP2 function - The present invention relates to the inhibition of the function of SHP2 by both anti-SHP2 peptides and the chemical compound 4-(2-sulfaminoethyl)benzoic acid, SEBA, and SEBA derivatives binding to the phosphotyrosyl phosphatase domain of SHP2 thereby inhibiting the function of SHP2 both in vitro and in vivo. In addition, the inhibition of SHP2 may be useful as a treatment for human disease, and it has been shown that interfering with SHP2 function using the anti-SHP2 peptides and SEBA compounds reverses cell transformation and induces remission of preformed tumors in vivo demonstrating a possible treatment for cancer. | 2009-02-12 |
20090042789 | Method for Improving Symptom of Mood Disorder - The present invention relates to a method for improving symptom of mood disorder or its related disorder comprising a step of allowing activated-type Gm1 protein and the like to be excessively present in a brain of a mammal, and a non-human mammal, to which the method has been applied, and the like. | 2009-02-12 |
20090042790 | TRANSMUCOSAL DELIVERY OF PEPTIDE DERIVATIVES - What is described is a biological agent, comprised of a biologically active protein, or a fragment or a mimetic thereof, conjugated to at least one poly(alkylene oxide) chain having a size less than about 20 kDa, pharmaceutical formulations for intranasal delivery of said biological agent, or uses of said biological agent in the manufacture of said pharmaceutical formulation for administering said biological agent to a mammal. | 2009-02-12 |
20090042791 | INTEGRIN BINDING MOTIF CONTAINING PEPTIDES AND METHODS OF TREATING SKELETAL DISEASES - Peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing at least one of an integrin binding motif such as an RGD sequence, a glycosaminoglycan binding motif, and a calcium binding motif, and the remainder of amino acids contiguous with the RGD sequence in matrix extracellular phosphoglycoprotein. The sequences may be formulated for injection or dispersed in toothpaste or a mouthwash or gum patch and administered to enhance bone/tooth growth and/or reduce excessive urinary phosphate loss from the body. | 2009-02-12 |
20090042792 | 18 HUMAN SECRETED PROTEINS - The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins. | 2009-02-12 |
20090042793 | Novel Antiviral Therapies - The field of the invention relates to the use of carbohydrate binding compounds as a medicine, their use to treat or prevent viral infections, their use to manufacture a medicine to treat or prevent viral infections and their use in a vaccination strategy. The present invention relates to the use of said compounds to manufacture a medicine to treat or prevent viral infections of subjects, more in particular infections with viruses having glycosilated envelop proteins such as Retroviridae (i.e. Lentivirinae), like HIV (human immunodeficiency virus), Flaviviridae, like HCV (hepatitis C virus), Hepadnaviridae, like HBV (hepatitis B virus), Coronaviridae, like SARS corona virus, and Orthomyxoviridae, like influenza A, B or C. | 2009-02-12 |
20090042794 | GROUP B STREPTOCOCCUS ANTIGENS AND CORRESPONDING DNA FRAGMENTS - The present invention relates to antigens, more particularly antigens of Group B | 2009-02-12 |
20090042795 | Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation - The present invention provide cardiac stem cell proliferation proteins and fragments thereof that promote proliferation and/or differentiation of cardiac stem cells. Also provided are methods of treating subjects with heart disease or defects, the methods comprising administering a cardiac stem cell proliferation protein or a fragment thereof to the subject in need of such treatment. | 2009-02-12 |
20090042796 | DERIVATIVES OF THE IL-2 RECEPTOR GAMMA CHAIN, THEIR PRODUCTION AND USE - This invention relates to the use of the IL-2 common gamma (cγc) and related molecules for the modulation of signal activities controlled by NIK, and some new such molecules | 2009-02-12 |
20090042797 | GAMMA-HEREGULIN - A novel member of the heregulin superfamily has been identified which is designated “γ-HRG”. This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner. γ-HRG polypeptide and nucleic acid are disclosed, together with various uses therefor (e.g. use of γ-HRG nucleic acid for the recombinant production of γ-HRG). γ-HRG antagonists (e.g. neutralizing antibodies and antisense nucleic acid molecules) as well as uses therefor are also described. | 2009-02-12 |
20090042798 | T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provids an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials. | 2009-02-12 |
20090042799 | CLOSTRIDIAL TOXIN DERIVATIVES AND METHODS FOR TREATING PAIN - Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds. | 2009-02-12 |
20090042800 | ASSAY - A method for determining the risk of an individual of suffering from inflammation, opportunistic infection or disruption of immunoglobulin metabolism, comprising (a) determining the level of fragmentation or modification of Fc function of immunoglobulins in a sample taken from the individual and (b) determining thereby the risk of inflammation, impaired immune response or opportunistic infection. The invention also provides the use of a trypsin inhibitor in the manufacture of a medicament for use in the treatment or prevention of a disorder associated with elevated trypsin activity which is correlated with IgG fragmentation or modification. | 2009-02-12 |
20090042801 | Method for inhibiting infection and reproduction of influenza type A WSN virus - The present invention relates to a method for inhibiting infection and reproduction of influenza type A WSN virus, which comprises providing an effective amount of a pharmaceutical composition; and contacting said composition with said influenza type A WSN virus, wherein said pharmaceutical composition contains C-phycocyanin (C-PC), allophycocyanin (APC), and spirulina growth factor (SGF). The present invention also provides a method for extracting said pharmaceutical composition, comprising the steps of: (a) adding hypotonic buffer solution to organic blue-green algae powder and mixing thoroughly; (b) incubating the mixture below room temperature overnight; (c) separating and purifying the mixture by a centrifuge; (d) collecting the suspending supernatant and detecting it by a spectrometer to determine ingredients and content; and (e) spray drying the supernatant; characterized in which low-temperature extraction is employed to maintain the bioactivity and nutrients of the pharmaceutical composition. | 2009-02-12 |
20090042802 | COMPOUNDS AND PEPTIDES THAT BIND THE KGF RECEPTOR - The present invention relates to peptide compounds that bind the KGF receptor. The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with defective or insufficient epithelial cell proliferation. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided. | 2009-02-12 |
20090042803 | INHIBITORS OF PROTEIN KINASES AND USES THEREOF - Compounds that are capable of inhibiting the activity of one or more protein kinases are provided. The compounds are short, predominantly basic peptidic compounds comprising between about 5 and about 20 amino acids, and can optionally comprise an ATP mimetic moiety. The protein kinase inhibiting compounds can be used to inhibit the activity of one or more protein kinases in vitro or in vivo. Also provided are methods of inhibiting a protein kinase in a subject by administration of an effective amount of a protein kinase inhibiting compound and the use of the protein kinase inhibiting compounds, alone or in combination with other chemotherapeutic agents, in the treatment of protein kinase mediated diseases and disorders. | 2009-02-12 |
20090042804 | NOVEL PEPTIDE AMPHIPHILES HAVING IMPROVED SOLUBILITY AND METHODS OF USING SAME - Disclosed herein are novel peptide amphiphile molecules and compositions discovered to possess improved solubility in aqueous buffers which, in turn, facilitates purification required for pharmaceutical applications, particularly for in vivo administration to human patients. In addition, gels of such peptide amphiphile compositions are shown herein to possess unexpectedly superior gelation kinetics and rheological properties, including an increased mechanical stiffness, which better mimics the mechanical properties of natural central nervous system tissues. | 2009-02-12 |
20090042805 | Peptides Useful As Dual Caspase-2/-6 Inhibitors And Their Biological Applications - The invention relates to peptides having a core sequence selected in the group comprising: SEQ ID No.1: VDEAD, SEQ ID No.2: LDEGD, SEQ ID No.3: VDEGD, SEQ ID No.4: VDESD, SEQ ID No.5: LDEKD, SEQ ID No.6: FDESD, SEQ ID No.7: LDEAD, application as inhibitors of caspase-2 and/or -6 activity. | 2009-02-12 |
20090042806 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF - Transglutaminase inhibitors and methods of use thereof are provided. | 2009-02-12 |
20090042807 | Oligopeptide treatment of ischemia reperfusion injury - The invention relates to the modulation of gene expression in a cell, also called gene control, in particular, in relation to the treatment of ischemic-reperfusion injury. The invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signaling molecule comprising a peptide or functional analogue thereof. The invention provides a method of treating ischemia-reperfusion injury in a subject by reducing NO production by the subject's macrophages, the method comprising: administering to the subject a composition comprising: means for reducing production of NO by a cell, together with a pharmaceutically acceptable excipient. | 2009-02-12 |
20090042808 | USE OF MITOCHONDRIA-TARGETED ELECTRON SCAVENGERS AS ANTI-INFLAMMATORY AGENTS - Provided herein are methods for using mitochondria-targeted electron scavengers as anti-inflammatory agents. The mitochondria-targeted electron scavenger comprises a free radical-scavenging group covalently linked to a mitochondria-targeting group derived from a hemigramicidin moiety. The mitochondria-targeted electron scavenger can be used to treat medical conditions associated with acute or chronic inflammation. | 2009-02-12 |
20090042809 | Blood Pressure Lowering Protein Hydrolysates - The present invention describes the tripeptide MAP and/or the tripeptide ITP and/or a salt thereof. | 2009-02-12 |
20090042810 | AMPK Deficient Animals, Screening Methods, And Related Therapeutics And Diagnostics - The invention provides transgenic | 2009-02-12 |
20090042811 | Synthesis of Glycerolipid Carbamates and Dicarbamates and Their Use as an Antitumor Compounds - The syntheses and in vitro antitumor properties of carbamate-containing, dicarbamate-containing, and ureido-containing phospholipid compounds that have an ether linkage at the C-1 position of a glycerol backbone, a carbamate, dicarbamate, or ureido moiety at the C-2 position of the glycerol backbone, and a phosphocholine, phosphonocholine, or glycoside moiety at the C-3 position of the glycerol backbone are described. The synthesis and antiproliferative activity of ether lipids with a naphthol moiety at the C-1 position are also described. These compounds were shown to be potent inhibitors of cancer cell growth. These compounds are useful for killing cancer cells and treating cancer. | 2009-02-12 |
20090042812 | Lipase inhibitors - The present invention provides lipase inhibitory agents comprising a gallotannin or ellagitannin component(s) isolated from teas or Tellima grandiflora as well as foods and beverages and medicines containing said inhibitory agents. | 2009-02-12 |
20090042813 | Hoodia extract oil compositions comprising medium chain triglycerides - Oil compositions containing | 2009-02-12 |
20090042814 | Treatment and Diagnosis of Obligate Intracellular Pathogens - This invention relates to the detection of pathogens, in particular persistent forms of obligate intracellular or membrane associated microorganisms such as | 2009-02-12 |
20090042815 | Macrolide Synthesis Process and Solid-State Forms - This invention relates to a method for making macrolides, and, in particular, a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, inter alia, may be used to make macrolides. This invention also relates to solvated and non-solvated crystalline forms of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from) such crystalline forms, methods for making medicaments comprising (or derived from) such crystalline forms, methods of treatment using such crystalline forms, and kits comprising such crystalline forms. | 2009-02-12 |
20090042816 | Synthetic Ligands For The Differentiation Of Closely Related Toxins And Pathogens - Synthetic ligand compounds and methods of differentiating between Shiga toxin 1 and Shiga toxin 2 are disclosed herein. Another embodiment includes a kit for differentiating between Shiga toxin 1 and Shiga toxin 2. Assay systems and methods for providing an assay are also provided for herein. | 2009-02-12 |
20090042817 | Use of an Active Ingredient Combination That Contains Hydroxystilbene for Preventing and/or Treating Diseases - The invention relates to the use of a combination of active ingredients, selected from resveratrol and piceatannol precursors and functional derivatives thereof, in addition to the use of the stereoisomeric forms of said ingredients, in the form of salts or phenol respectively, for producing an agent for the prevention and/or treatment of diseases, whose occurrence and/or progress is associated with an increased IL-6 serum level and/or whose occurrence and/or progress can be treated by a dose of a selective oestrogen receptor β (ER-β) agonist. | 2009-02-12 |
20090042818 | Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists - The disclosure provides compositions comprising liquiritigenin, or derivatives, or prodrugs, useful as estrogen receptor beta selective agonists. The disclosure also provides methods of treating menopausal symptoms, and estrogen-dependent disorders, with said compositions. | 2009-02-12 |
20090042819 | Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use - The invention describes novel organic nitric oxide donor salts of a antimicrobial compounds, and novel compositions and kits comprising at least one organic nitric oxide donor salt of an antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. In one embodiment the antimicrobial compounds of the invention are aztreonam, ciprofloxacin, doripenam, duramycin and tobramycin. The organic nitric oxide donors that form salts are preferably organic nitrates, organic nitrites, nitrosothiols, thionitrites and heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. The methods of the invention are preferably for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating | 2009-02-12 |
20090042820 | Tubulin Binding Anti Cancer Agents And Prodrugs Thereof - Novel tubulin binding compounds and hypoxia activated prodrugs of novel and known tubulin binding compounds useful for treating cancer and other hyperproliferative diseases are disclosed. | 2009-02-12 |
20090042821 | STABLE DOSAGE FORMS OF SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS - The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w. | 2009-02-12 |
20090042822 | METHOD TO ENHANCE DELIVERY OF GLUTATHIONE AND ATP LEVELS IN CELLS - A therapeutic method is provided comprising treating a mammal subject to hypoxia with an amount of 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid (RibCys) or a pharmaceutically acceptable salt thereof effective to both maintain, restore or increase both the ATP levels and the glutathione (GSH) levels in said tissue. | 2009-02-12 |
20090042823 | USES OF BROAD SPECTRUM RNAI THERAPEUTICS AGAINST INFLUENZA - Methods and uses of RNAi-inducing agents for medicaments and treating or preventing a viral infection. | 2009-02-12 |
20090042824 | Methods and Kits for Linking Polymorphic Sequences to Expanded Repeat Mutations - Methods and kits are provided for determining which single nucleotide polymorphism (“SNP”) variant of an allele of a heterozygous patient is on the same allele as a disease-causing mutation that is at a remote region of the gene's mRNA comprising a) an allele specific reverse transcription reaction using an allele specific primer which recognizes one SNP variant, wherein further the 3′ end of the primer is positioned at the SNP nucleotide position, and b) analysis of the resulting cDNA product from the reverse transcription reaction at the region of the mutation to determine the presence or absence of the mutation on this allele specific cDNA product, wherein the allele specific primer is shorter than about 20 nucleotides. | 2009-02-12 |
20090042825 | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer - Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient. | 2009-02-12 |
20090042826 | Use of the AXL receptor for diagnosis and treatment of renal disease - The invention is directed to a process of identifying a compound capable of inhibiting the activity of a human Axl receptor that comprises contacting the Axl receptor or cells expressing the Axl receptor with the compound; measuring the Axl receptor activity in the presence of the compound; and comparing the activity measured to that measured in the absence of the compound under controlled conditions, wherein a decrease identifies the compound as being capable of inhibiting the activity. Therapeutic and diagnostic applications are also described. | 2009-02-12 |
20090042827 | ANTIVIRAL OLIGONUCLEOTIDES TARGETING HBV - Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action. | 2009-02-12 |
20090042828 | METHODS AND COMPOSITIONS FOR TREATING GAIN-OF-FUNCTION DISORDERS USING RNA INTERFERENCE - The present invention relates to novel methods for treating dominant gain-of-function diseases. The invention provides methods for targeting regions of the copper zinc superoxide dismutase (SOD1), which causes inherited amyotrophic lateral sclerosis (ALS), with RNAi agent. The invention further provides RNAi resistant replacement genes containing mismatches with their respective RNAi agents. The invention also provides for vectors that express RNAi agent and RNAi resistant replacement gene of the present invention. | 2009-02-12 |
20090042829 | Nucleic Acid-Lipopolymer Compositions - Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient. | 2009-02-12 |
20090042830 | NOVEL ONCOGENE, RECOMBINANT PROTEIN DERIVED THEREFROM, AND USES THEREOF - The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No. 1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No. 2. | 2009-02-12 |
20090042831 | USE OF 5'-METHYLTHIOADENOSINE (MTA) IN THE PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES AND/OR TRANSPLANT REJECTION - 5′-methylthioadenosine (MTA), its pharmaceutically acceptable salts and/or prodrugs may be used in the prevention and/or treatment of autoimmune diseases, such as, for example, Multiple Sclerosis (MS), as well as in the prevention and/or treatment of transplant rejection. | 2009-02-12 |
20090042832 | NOVEL SALTS OF BOSWELLIC ACIDS AND SELECTIVELY ENRICHED BOSWELLIC ACIDS AND PROCESSES FOR THE SAME - New salts or ion pair complexes obtained by a reaction between boswellic acids or selectively enriched 3-O-acetyl-11-keto-β-boswellic acid (AKBA) or 11-keto-β-boswellic acid (KBA) compounds obtained through a new improved process, and an organic amine, more particularly with glucosamine. These salts or ion pair complexes are useful in nutraceuticals and in food supplements for anti-inflammatory and analgesic treatment of joints and cancer prevention or cancer therapeutic agents. These salts or ion pair complexes could also be used in cosmetic or pharmaceutical composition for external treatment of body parts or organs to treat inflammatory diseases or cancer. | 2009-02-12 |
20090042833 | PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF OSTEOARTHRITIS CONTAINING CLODRONIC ACID AND HYALURONIC ACID - Disclosed are pharmaceutical compositions containing clodronic acid and hyaluronic acid or their salts as active constituents, mixed with suitable vehicles. | 2009-02-12 |
20090042834 | Stabilized Glycosaminoglycan Preparations and Related Methods - Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.) | 2009-02-12 |
20090042835 | COMPOSITIONS AND METHODS FOR AMELIORATING HYPERLIPIDEMIA - The invention provides compositions comprising a pharmaceutical compound having one or more Microsomal Triglyceride Transfer Protein (MTP) inhibitors that are covalently linked to one or more Liver Fatty Acid-Binding Protein (L-FABP) inhibitors. Also disclosed are methods for using the inventive pharmaceutical compositions in the treatment of hepatic steatosis and hyperlipidemia while avoiding the harmful side effects of steatorrhea. | 2009-02-12 |
20090042836 | Proteasome inhibitors - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2009-02-12 |
20090042837 | LEPTOMYCIN COMPOUNDS - Leptomycin-type compounds according to formula I | 2009-02-12 |
20090042838 | PHOSPHAPLATINS AND THEIR USE IN THE TREATMENT OF CANCERS RESISTANT TO CISPLATIN AND CARBOPLATIN - The present invention provides phosphaplatins, stable isolated monomeric phosphate complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes-unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents-do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art. | 2009-02-12 |
20090042839 | Crystalline forms of ibandronate sodium - Provided are crystalline forms of ibandronate sodium, as well as processes for the preparation thereof. | 2009-02-12 |
20090042840 | Phospholipids for Use in the Treatment of an Allergic Inflammatory Condition - A phospholipid comprising a diacyl-substituted phosphatidyl group and a pharmaceutical composition comprising such a phospholipid for use in treatment of an allergic inflammatory condition and a method for the treatment of an allergic inflammatory condition. The phospholipid is particularly a mixture of phospholipids known as pumactant. | 2009-02-12 |
20090042841 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS - This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD). | 2009-02-12 |
20090042842 | Analogues of cilostazol - This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of an phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol. | 2009-02-12 |
20090042843 | Inhalation Device Containing Plural Doses of a Pharmaceutical Composition - The invention relates to an inhalation device comprising plural of doses of a pharmaceutical composition in powder form, wherein the pharmaceutical composition comprises one or more, preferably one, anticholinergic, optionally in combination with a pharmaceutically acceptable excipient. | 2009-02-12 |
20090042844 | 17ALPHA-SUBSTITUTED STEROIDS AS SYSTEMIC ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS - Compounds having the structure, their salts or N-oxide derivatives: | 2009-02-12 |
20090042845 | Suppression and prevention of tumors - Combinations of betaine and vitamin C are used to suppress or prevent malignant tumors, e.g., by combining the two ingredients in a product consumed by a human, dog, or cat, such as an aqueous liquid such as grape juice, the ingredients being provided in containers with instructions for use, or in finished products, especially with support of tests demonstrating the effectiveness of the treatment for, e.g., preventing tumors in populations known to be at risk of developing tumors, or, treating existing cancers in combination with other cancer drugs such as anastrozole and/or fulvestrant and/or artemisinin either concurrently or sequentially to prevent the cancer from growing when the cancer drug is not being used, the combination of betaine and Vitamin C optionally being supplemented or replaced by other treatments like the combination of selenium and Vitamin E or hormone treatments used to slow cancer growth. | 2009-02-12 |
20090042846 | Topical Delivery System for Phytosterols - This invention relates to certain sugar esters of phytosterols of formula (I). These esters are useful for topical application, and for the treatment of skin condition, including age spots, acne, loss of cellular antioxidants, collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles including fine lines, oxidation, damage from radiation, malfunction of matrix metalloproteases, malfunction of tyrosinases, damage from free radicals, damage from UV, dry skin, xerosis, ichthyosis, dandruff, brownish spots, keratoses, melasma, lentigines, liver spots, pigmented spots, dark circles under the eyes, skin pigmentation including darkened skin, blemishes, oily skin, warts, eczema, pruritic skin, psoriasis, inflammatory dermatoses, topical inflammation, disturbed keratinization, skin changes associated with aging, nail or skin requiring cleansers, conditioning or treatment, and hair or scalp requiring shampooing or conditioning, and combinations thereof; | 2009-02-12 |
20090042847 | 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN POLYMORPHS AND FORMULATIONS - Polymorphs and pharmaceutical formulations of 17-allylamino-17-demethoxy-geldanamycin (17-AAG). | 2009-02-12 |
20090042848 | COPPER COMPLEXES - There are described mononuclear copper complexes having anti-inflammatory activity. The complexes include copper complexes of indomethacin. There are also provided methods for the prophylaxis or treatment of inflammation comprising administering such complexes to a mammalian subject. | 2009-02-12 |
20090042849 | Phosphorylation of 5-lipoxygenase at ser523 and uses thereof - The present invention provides novel mechanisms that regulate the production of anti-inflammatory and pro-inflammatory mediators generated by 5-lipoxygenase. In this regard, the present invention establishes that phosphorylation of 5-Lipoxygenase by protein kinase A, has a crucial role in determining the end products of 5-Lipoxygenase. With translocation to the nucleus, potent proinflammatory leukotrienes are produced, whereas following phosphorylation by protein kinase A, anti-inflammatory mediators are produced. The present invention also discloses compounds that regulate these pro- and anti-inflammatory mediators. | 2009-02-12 |
20090042850 | COMPOSITIONS AND METHODS FOR CYTOPROTECTION - The present invention provides compositions and methods for cytoprotection. In particular, it provides zinc chelate compositions comprising at least one zinc ion and at least one aminothiol ligand. | 2009-02-12 |
20090042851 | SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS ANTAGONISTS OF OREXIN 2 RECEPTORS - The present invention is directed to a compound of formula (I): | 2009-02-12 |
20090042852 | Novel Pyridine Compounds - The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them. | 2009-02-12 |